Articles by Jennifer B. Green, MD

Authors’ Reply to “Comment on Generalizability of GLP-1 RA CVOTs in US T2D Population”
ByEric T. Wittbrodt, PharmD, MPH,James M. Eudicone, MS, MBA,Kelly F. Bell, PharmD, MSPhr,Devin M. Enhoffer, PharmD,Keith Latham, PharmD,Jennifer B. Green, MD The authors of the manuscript “Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials Enrollment Criteria to the US Type 2 Diabetes Population” respond to a letter to the editor.

Eligibility Varies Among the 4 Sodium-Glucose Cotransporter-2 Inhibitor Cardiovascular Trials: Implications for the General Type 2 Diabetes US Population
ByEric T. Wittbrodt, PharmD, MPH,James M. Eudicone, MS, MBA,Kelly F. Bell, PharmD, MSPhr,Devin M. Enhoffer, PharmD,Keith Latham, PharmD,Jennifer B. Green, MD 
Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials Enrollment Criteria to the US Type 2 Diabetes Population
ByEric T. Wittbrodt, PharmD, MPH,James M. Eudicone, MS, MBA,Kelly F. Bell, PharmD, MSPhr,Devin M. Enhoffer, PharmD,Keith Latham, PharmD,Jennifer B. Green, MD